The contrast arose because the study evaluated the same water chemistry against two different toxicological bases. The drinking-water guideline and the toxicological reference values are revised independently, so compliance with a concentration guideline does not necessarily provide a current assessment of health risk. The authors do not characterize the arsenic guideline as flawed. Instead, their results show a structural disconnect between regulatory compliance and contemporary toxicological evidence, demonstrating that a water supply can meet guideline-based quality classifications while producing substantially different risk estimates after arsenic toxicity information is updated.

Trace-element measurements showed that arsenic was the principal contributor to cumulative risk in this system. The researchers quantified 17 elements by inductively coupled plasma mass spectrometry, then assessed health risk deterministically and probabilistically. Arsenic concentrations were correlated with antimony, lithium, and boron, a pattern consistent with a shared geogenic source rather than treatment-related contamination. Municipal and spring samples also had broadly similar trace-element profiles. These observations connect arsenic exposure to the basin’s geothermally influenced geology, although the supplied findings do not establish the precise contribution of any individual geological or treatment process.

Monte Carlo simulation indicated that the difference between the updated and legacy arsenic values was robust to uncertainty in exposure parameters. In other words, varying modeled exposure conditions did not remove the divergence: the revised arsenic toxicity inputs continued to produce higher risk classifications than the older values for the same samples. The result supports the conclusion that updated toxicological information, rather than a change in water quality, drove the reclassification. It also shows why a health-risk assessment based only on a regulatory guideline may not capture the implications of newer dose-response information.

The study is a focused environmental-health assessment rather than a nationwide survey or a clinical investigation. It covers one basin-fed drinking-water system, 42 samples and ten districts in Eskişehir, and its modeled results should not automatically be generalized to other aquifers, cities or water-source types. The reported outcomes are estimates derived from measured water chemistry and toxicological inputs, not observations of diagnosed illness among residents. Even with those limits, the case study has implications beyond arsenic: it demonstrates that unchanged samples can receive a different health-risk interpretation when reference values are revised, and that cumulative assessment of multiple trace elements may reveal risks not apparent from a guideline exceedance count alone.

Subject of Research: Arsenic-based health-risk reassessment of a geothermally influenced drinking-water basin in Eskişehir, Türkiye

Article Title: Updated arsenic toxicity values substantially alter health-risk interpretation in a regulation-compliant, geothermally influenced basin-fed drinking-water system

Article References: Çetinkaya, S., Benkli, A. B., & Erdem, O. (2026). Updated arsenic toxicity values substantially alter health-risk interpretation in a regulation-compliant, geothermally influenced basin-fed drinking-water system. Environmental Geochemistry and Health, 48(16), Article 652. https://doi.org/10.1007/s10653-026-03489-x

Image Credits: AI Generated

DOI: 10.1007/s10653-026-03489-x

Keywords: arsenic, drinking water, health risk, Eskişehir, toxicology, ICP-MS, Monte Carlo simulation, geogenic contamination, Hazard Index, water quality, Updated, toxicity

The review reports that existing research is concentrated in journals categorized within the first and second quartiles. China, the United States and Canada were identified as the leading contributors to the analyzed literature. It also detected a shift in research attention from microplastics toward nanoplastics, which the authors associated with advances in understanding fragmentation processes and environmental impacts.

The analysis identifies drinking water as a research area that needs greater attention. The abstract says future work should prioritize development of effective removal technologies, reductions in nanoplastic release within drinking-water distribution systems, and reliable analytical methods suitable for routine monitoring. These are recommendations for future research, rather than evidence that particular treatment or monitoring approaches are already effective.

For policy, the authors call for legislative frameworks that define monitoring protocols, limit values and risk-assessment strategies for nanoplastics in drinking water. The abstract states that standardized regulations are currently absent and frames their development as an urgent need. Because the supplied evidence consists only of the article’s abstract and publication page, the analysis does not permit assessment of the full methods, search strategy beyond the Web of Science database and stated period, classifications of individual papers or the robustness of the findings. The page also states that the early-access version remains subject to further edits and will be replaced by the final version of record.

Subject of Research: Bibliometric analysis of nanoplastics research in drinking water

Article Title: Bibliometric analysis of nanoplastics in drinking water and policy implications

Article References: Praus, P. (2026). Bibliometric analysis of nanoplastics in drinking water and policy implications. Discover Sustainability. https://doi.org/10.1007/s43621-026-04938-4

Image Credits: AI Generated

DOI: 10.1007/s43621-026-04938-4

Keywords: nanoplastics, drinking water, bibliometric analysis, research priorities, water treatment, analytical methods, distribution systems, environmental pollution, toxicology, water policy, Bibliometric, analysis

The commission’s recommendations support implementation of Germany’s Hazardous Substances Ordinance and cover airborne workplace limits, biological monitoring values and biological reference values. The revised assessment of manganese and its inorganic compounds was among the ten changes made to current airborne exposure recommendations. Drawing on evidence from several commission working groups, the commission concluded that exposure to 0.05 mg of manganese per cubic metre of air is not expected to cause adverse health effects.

Manganese is especially relevant to metalworking because welding can generate dusts and fumes containing very small manganese particles. After absorption through the alveoli of the lungs, such particles can be distributed throughout the body and accumulate in the brain, where they can produce neurotoxic effects. For the manganese reassessment, the commission assessed 50 new studies.

These included large epidemiological cohort studies from Australia, South Africa and the United States, together with magnetic resonance imaging examinations of affected brain regions. Christoph van Thriel, head of the commission’s Working Group on Neurotoxicity and Sensory Systems and professor of neurotoxicology and chemosensory research at the Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund University, said the studies were systematically compiled, correlated and evaluated in accordance with the commission’s assessment criteria. The evidence review combined epidemiological observations with brain imaging, supporting the commission’s scientific evaluation of airborne manganese exposure.

The commission’s annual List of MAK and BAT Values, now available in English, brings together recommendations for limiting hazardous exposures in occupational settings. A MAK value, or maximum workplace concentration, specifies the concentration of a substance in workplace air that is not expected to cause long-term harm when present as a gas, vapour or aerosol. The list also includes biological values derived from measurements in blood or urine.

These measurements allow occupational physicians and toxicologists to assess individual exposure resulting from contact with workplace substances. The recommendations therefore address both what may be present in workplace air and what has been absorbed by an exposed person. A biological work substance tolerance value, abbreviated BAT, corresponds to the concentration of a substance or its metabolites in blood or urine that a person can be exposed to throughout a working life without adverse health effects.

The list also contains biological reference values, known as BAR, which can be used to assess the extent of occupational exposure. The commission revised biological tolerance values in blood or urine for six substances in this year’s list, including sevoflurane, inorganic lithium compounds and strontium. These are values for assessing exposure through biological monitoring, and their use in occupational medicine is based on the scientific evaluation for the individual substance.

Three substances were newly added to the list of recommendations: benzophenone, melamine and p-toluenesulfonic acid. Benzophenone is used as a photoinitiator in the printing industry, in chemical synthesis and as a fragrance ingredient in cosmetic products. Melamine is used in the manufacture of melamine resins, which are employed in plastics and adhesives.

The newly established BAT value of 300 µg melamine per litre of urine provides a health-based reference value for assessing exposure in people who have absorbed melamine. This is an individual biological monitoring value rather than a new general limit on melamine in workplace air. For p-toluenesulfonic acid, described as a strong acid, the commission derived a MAK value of 0.2 mg/m³.

The compound is used as a catalyst in chemical synthesis, as a curing agent and as a descaling agent. Its addition therefore brings the substance into both the airborne exposure and occupational-health assessment framework maintained by the commission. As with the other entries, the values are accompanied by detailed scientific justifications, allowing readers to examine the evidence and the assessment methods used for the substances reviewed.

The complete documentation and method descriptions are available through the commission’s MAK Collection. The proposed amendments and new additions remain open for discussion until 31 December 2026. During that period, new data or scientific comments may be submitted to the commission.

This consultation period is part of the commission’s process for keeping its recommendations current with scientific findings. The open review does not itself create binding workplace rules, nor does it determine whether regulations will be adopted. Instead, the recommendations proceed through the stated regulatory route: initial assessment by the Federal Ministry of Labour’s Committee on Hazardous Substances and the drawing up of statutory regulations where necessary.

Over the past year, the commission published 70 outputs, including 40 MAK documentation reports, 10 BAT documentation reports, 10 descriptions of air-monitoring methods and 10 biomonitoring methods. Andrea Hartwig, commission chair and professor at the Karlsruhe Institute of Technology, said the publication volume reflected the voluntary commitment of scientists working together across disciplines within the commission. International access to the commission’s work has also increased.

Since spring 2026, new publications from the Permanent Senate Commission have been indexed in the US National Library of Medicine databases PubMed and PubMed Central. Hartwig said the inclusion reflected the quality and relevance of the commission’s work for evidence-based occupational health and safety worldwide. Substance documentation reports and method descriptions are available in the MAK Collection, while the commission’s other publications are available on an open-access basis so that the knowledge can be reused for scientific purposes.

The 2026 list thus combines reassessed exposure evidence, revised biological monitoring values, new substance entries and expanded access to the supporting scientific and methodological material.

Subject of Research: DFG assessment of occupational exposure limits and biological monitoring values for workplace chemicals

Article Title: Health and safety at work: DFG Senate Commission assesses the risk of chemical compounds

Article References: Health and safety at work: DFG Senate Commission assesses the risk of chemical compounds. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: occupational health, workplace exposure limits, hazardous chemicals, manganese, biological monitoring, welding fumes, neurotoxicology, chemical risk assessment, DFG, toxicology, Health, safety

The research, conducted by scientists at the Helmholtz Centre for Environmental Research (UFZ) together with the Food Packaging Forum, forms part of the co-creation project CoModHaz, led by Professor Escher of UFZ. The project’s ambitious goal is to develop high-throughput, animal-free testing methods for hazard screening of chemicals, their transformation products, and mixtures. The Food Packaging Forum participates as a project partner alongside regulators and industry stakeholders, ensuring the resulting tools reflect the needs of those who will ultimately use them.

At the heart of the study lies a sophisticated analysis of Adverse Outcome Pathways, or AOPs. These frameworks describe the chain of biological events that link a molecular initiating event, such as a chemical binding to a receptor or disrupting an enzyme, through successive levels of biological organization, ultimately culminating in an adverse health outcome like cancer or metabolic disease. The researchers systematically mapped 266 AOPs associated with six major disease groups: cancer, reproductive disorders, metabolic disease, immunological disorders, cardiovascular disease, and brain-related disorders.

Rather than treating each pathway as an isolated chain of events, the team analyzed the pathways as interconnected networks. This network-based perspective revealed biological events where the pathways diverge, converge, or occupy central positions in promoting the different diseases. Such convergence points are scientifically valuable because a single toxicological effect at a key node can ripple outward to influence multiple disease outcomes, meaning a relatively compact set of tests can capture a broad spectrum of potential hazards.

From this analysis emerged a practical outcome: a set of 15 high-throughput bioassay tests capable of checking whether a product on the market contains chemicals that could contribute to any of the six disease groups. The panel was selected according to criteria of simplicity, robustness, and high-throughput compatibility, meaning the assays can process large numbers of samples efficiently. Crucially, the multiplexed design allows screening of individual chemicals or chemical mixtures, addressing a major gap in conventional testing regimes.

That gap is substantial. Current testing approaches cannot effectively check for all possible health outcomes, and many regulatory testing requirements examine only genotoxicity, whether a substance damages genetic material, while testing just one substance at a time. This stands in stark contrast to real-world exposure. Widespread evidence shows that consumers are simultaneously exposed to complex mixtures of different chemicals from all types of products, so single-substance assessments may miss interactive effects and cumulative risks that matter for health.

One immediate application of the new tests involves food contact materials. Food packaging can contain many non-intentionally added substances, chemicals that migrate from inks, adhesives, coatings, recycled materials, or processing aids and are often unknown and therefore untested. Screening the food packaging actually available on the market with the proposed assay panel would provide a systematic way to flag hazardous compounds that have escaped regulatory scrutiny, turning an intractable data gap into a manageable testing workflow.

Dr. Sarah Stevens, lead author of the study from the Helmholtz Centre for Environmental Research, emphasized the practical significance of the work. By translating the prioritized endpoints into in-vitro assays suitable for high-throughput screening, she said, the results become actionable, and the proposed panel of 15 assays could enable much broader toxicological screening of chemicals than is currently standard practice. She described this as a significant improvement in protecting public health from hazardous chemicals present across a wide range of products used daily.

Dr. Jane Muncke, co-author of the study from the Food Packaging Forum, framed the research as an important milestone in improving how chemicals are tested. New testing methods of this kind, she noted, can lead to breakthroughs in disease prevention because they enable systematic identification of exposures to hazardous chemicals in everyday products. Since non-communicable diseases such as cancer, cardiovascular disease, and metabolic disorders account for the majority of deaths globally, tools that help identify and mitigate chemical contributors could carry substantial preventive value.

Important work remains before the panel can be deployed at scale. In a next step, the proposed bioassay tests must be validated to determine how effectively they flag chemicals already known to be hazardous, establishing the method’s sensitivity and reliability against established toxicological benchmarks. A study applying the approach to food contact chemicals from food packaging is already underway, providing an early real-world test of the concept. The researchers describe the proposed tests as a pragmatic and promising starting point, one designed to evolve as new knowledge and testing technology become available, with the ultimate aim of better protecting consumers from the chemical exposures woven into modern daily life. The study, Mapping disease-linked AOPs to inform bioassay selection for chemical hazard assessment, was published in Environment International.

Subject of Research: Mapping adverse outcome pathways to select in vitro bioassays for chemical hazard screening across six disease groups

Article Title: Scientists make progress in mapping chemicals to six groups of common diseases

Article References: Scientists make progress in mapping chemicals to six groups of common diseases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: chemical hazard assessment, adverse outcome pathways, in vitro bioassays, food packaging, high-throughput screening, non-communicable diseases, toxicology, chemical mixtures, Environment International, public health, CoModHaz, animal-free testing

The team used a visible/near-infrared dual fluorescence labeling technique combined with non-invasive imaging to track the gastrointestinal fate of ingested nanoplastics. This approach allowed them to follow the particles through living animals without sacrificing them at every time point. Twenty-four hours after oral intake, the estimated retention rates of nanoplastics-associated fluorescence were two times lower in mice fed a medium fiber diet and seven times lower in mice fed a high fiber diet, compared with animals on a standard fiber diet.

The protective effect extended beyond simple retention. During a 28-day oral exposure to nanoplastics, mice on the high fiber diet showed attenuated damage to the intestinal epithelium—the single-cell layer that normally acts as a selective barrier between the gut contents and the bloodstream. Preserving this barrier matters because a compromised epithelium is the primary route by which nanoparticles and other harmful molecules gain systemic access.

Imaging also revealed a striking difference in where the particles ended up. Mice consuming the high fiber diet had declined detectable near-infrared fluorescence in important organs such as the liver, suggesting that less nanoplastic material was crossing the gut wall and accumulating systemically. The liver, which filters blood arriving from the digestive tract, is a key sentinel organ for ingested contaminants, so reduced hepatic signal implies reduced translocation.

To understand the mechanism, the researchers turned to in vitro simulations. These experiments showed that dietary fiber physically encapsulates and adheres to nanoplastics, decreasing their bioavailability. In other words, fiber acts as a molecular trap: it wraps around the tiny plastic fragments and binds them, making them less available for absorption through the intestinal lining. This physical sequestration likely explains both the lower retention rates and the reduced organ fluorescence observed in vivo.

The findings carry particular weight because nanoplastic exposure is essentially unavoidable. Unlike many environmental contaminants that can be regulated at the source, plastics degrade continuously into ever-smaller particles that contaminate air, water, and food chains worldwide. Estimates suggest humans ingest thousands to millions of plastic particles annually, though precise quantification remains challenging due to detection limits and the diversity of particle sizes and polymer types. Nanoplastics are especially concerning because their small size allows them to interact with biological membranes in ways larger microplastics cannot.

Previous research on microplastics and nanoplastics has documented a range of potential adverse effects in animal models, including intestinal inflammation, altered gut microbiota, oxidative stress, and metabolic disruption. However, as the authors note, approaches for reducing gastrointestinal nanoplastic exposure remain poorly explored. Most attention has focused on characterizing exposure and documenting harm rather than on practical interventions that individuals or public health authorities could implement.

Dietary fiber is an attractive candidate for such an intervention because it is already widely recommended for other health benefits, including cardiovascular protection, improved glycemic control, and colorectal cancer prevention. If the same dietary component that supports general health also sequesters nanoplastics, the public health implications could be substantial. Fiber-rich foods such as whole grains, legumes, fruits, and vegetables are inexpensive, accessible, and already the subject of extensive dietary guidance.

Several caveats temper the enthusiasm. The study was conducted in male mice, and sex-specific differences in gut physiology, transit time, and mucus composition mean the findings may not translate directly to females or to humans. The fiber doses and nanoplastic concentrations used in the animal model may not correspond to typical human exposures. Additionally, the dual fluorescence labeling technique tracks particle-associated signal, which may not perfectly represent the behavior of all nanoplastic types encountered in real diets, which vary in polymer composition, shape, and surface chemistry.

Nevertheless, the study represents a meaningful step toward actionable exposure reduction. By demonstrating that a common dietary component can measurably alter the gastrointestinal fate of nanoplastics—reducing retention, protecting the intestinal barrier, and limiting organ accumulation—the work provides a scientific basis for developing dietary strategies aimed at reducing nanoplastic exposure. Future research will need to identify which specific fiber types are most effective, determine optimal intake levels, and validate the findings in human studies. For now, the message is a familiar one with a new twist: eating more fiber may do more than feed your gut bacteria—it may help keep plastic out of your tissues.

Subject of Research: Health & Medicine

Article Title: High fiber diet mitigates exposure risk of nanoplastics in male mice

Article References: Yu, Z., Abulipizi, G., Fang, Y., Qu, C., Ding, L., Zong, Z., Huang, J., Chen, Z., Zhou, J., Li, Z., & Zeng, E. Y. (2026). High fiber diet mitigates exposure risk of nanoplastics in male mice. Nature Communications. https://doi.org/10.1038/s41467-026-78675-7

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78675-7

Keywords: nanoplastics, dietary fiber, gut health, microplastics, toxicology, nutrition, environmental health, Nature Communications, High, fiber, diet, mitigates

The scientific case rests on a remarkable convergence of biological properties. Zebrafish embryos develop outside the mother, with most organs forming within 24 hours of fertilization, and remain optically transparent for the first few days of life. This allows researchers to watch organogenesis, tumor growth, immune cell migration, and cardiac function unfold in real time inside a living vertebrate. A single breeding pair produces hundreds of eggs per week, fish reach sexual maturity in roughly three months, and maintenance costs are a fraction of those for mammalian colonies. Crucially, around 80 percent of human disease-linked genes have zebrafish orthologs, and core molecular processes—signal transduction, endocrine regulation, immune responses, and xenobiotic metabolism—are highly conserved, including functional counterparts of key drug-metabolizing enzymes and transporters. Modern genome-editing tools such as CRISPR/Cas9, Cre-lox systems, and transgenesis have all been adapted for the fish, enabling precise disease modelling and high-throughput in vivo screening at a scale unattainable in rodents.

The ethical architecture of the recommendations is anchored in the 3Rs framework of Replacement, Reduction, and Refinement, now extended by proposals for a fourth R, Responsibility, and a fifth R, Rehoming. The Society specifically recommends using embryos and larvae up to the stage preceding independent feeding—commonly around five days post-fertilization—for in vivo experiments. This timing matters legally as much as ethically: EU Directive 2010/63/EU defines its scope of protection with reference to independently feeding larval forms, meaning zebrafish embryos and early larvae fall outside the Directive’s formal scope. Polish national legislation, through the Act of 15 January 2015 on the protection of animals used for scientific or educational purposes, mirrors this exclusion. In practical terms, experiments on zebrafish embryos and early larvae may constitute a genuine legal alternative to classical protected-stage experiments, contributing to the replacement or reduction of mammalian models where scientifically appropriate. When later developmental stages or adult fish are required, the Society insists on approval from the competent Local Ethics Committee for Animal Experiments.

Nowhere is the model’s power more vivid than in oncology. The Society recommends the human-zebrafish xenograft approach, in which human cancer cells—from established lines or directly from patients—are implanted into zebrafish embryos or larvae. Because the larval immune system is not yet fully functional during the first days of life, human cells engraft and proliferate without immunosuppression. The transparent body permits direct visualization of tumor development, angiogenesis, and metastasis at single-cell resolution, and unlike in mouse models, human cancer cells in zebrafish readily migrate and form metastases, allowing drug effects on this critical aspect of tumor biology to be assessed under true in vivo conditions. Xenograft experiments can be completed in less than a week, whereas analogous mouse studies typically require several weeks. This so-called Avatar strategy is already entering clinical contexts: in a translational study involving breast cancer patients, complete concordance was demonstrated between chemotherapy responses observed in the larval model and the actual clinical responses, confirming high predictive value for personalized medicine. The model has also delivered clinically validated drugs—larval zebrafish studies revealed thalidomide’s strong inhibitory effect on tumor angiogenesis through suppression of VEGF signaling, helping establish thalidomide and its derivatives as therapies for neovascularization-dependent cancers such as multiple myeloma.

In toxicology, the recommendations position zebrafish as a tiered pre-filter for chemical and pharmaceutical safety. The Fish Embryo Acute Toxicity Test, standardized under OECD TG 236, determines lethal concentration values over a 96-hour exposure window in embryos, providing early hazard identification without adult vertebrates. While LC50 endpoints are not directly equivalent to rodent LD50 values, they deliver comparable information on acute toxicity and are primarily used for screening and prioritization rather than direct regulatory substitution. Embryonic transparency enables direct observation of teratogenic and embryotoxic potential, revealing morphological abnormalities, oxidative stress, apoptosis, and endocrine disruption induced by pharmaceuticals or contaminants. The assay’s compatibility with multi-well plate formats, robotic microscopes, computerized readers, and artificial intelligence allows automated detection of embryo orientation and organ-specific analysis of the heart, brain, or vessels. Regulatory recognition is growing: the FET assay is incorporated into OECD guidelines as an accepted alternative for chemical safety assessment, the US Food and Drug Administration acknowledges zebrafish for investigative and early-screening preclinical procedures, and the European Medicines Agency has expressed strong interest in preliminary regulatory reviews. The Society cautions, however, that zebrafish should not be regarded as a universal replacement where regulatory frameworks demand mammalian data on pregnancy, lactation, multigenerational endpoints, or long-term systemic organ toxicity.

Neurology and neuropsychiatry showcase the model’s translational depth. Zebrafish possess a hypothalamic–pituitary–interrenal axis homologous to the mammalian stress axis, with conserved cortisol synthesis, alongside well-organized serotonergic, dopaminergic, glutamatergic, and GABAergic neurotransmitter systems. Epilepsy research has been transformed by two complementary approaches: seizures can be induced in larvae with pentylenetetrazole, and genetic models based on the scn1lab gene—which corresponds to the human SCN1A gene mutated in Dravet syndrome—faithfully recapitulate reduced GABAergic signaling, spontaneous seizures, and abnormal neuronal activity. High-throughput phenotypic screening in multi-well formats using automated locomotor tracking and local field potential recordings identified clemizole as a potent seizure suppressor in the scn1lab model, and the same pipeline has highlighted serotonergic modulators such as fenfluramine and unexpected compound classes including synthetic cannabinoids. Classical antidepressants like fluoxetine and citalopram induce behavioral effects in zebrafish consistent with their human actions, and standardized larval assays—open-field thigmotaxis, light–dark preference, and light–dark challenge tests—quantify anxiety-like behavior with high predictive value. Social behavior assays in older larvae and juveniles have even been applied to model neurodevelopmental conditions relevant to autism spectrum disorders.

Metabolic disease research exploits the model’s conserved endocrine machinery. Zebrafish retain homologous insulin, glucagon, nuclear receptors, and appetite-regulating pathways; more than 70 percent of carbohydrate and glucose metabolic genes are conserved across zebrafish, frog, chicken, mouse, and human, with 57 percent linked to human type 2 diabetes. Larval insulin resistance models generated through elevated glucose, dexamethasone, or exogenous insulin exposure display features of impaired glucose handling suitable for evaluating antidiabetic drug candidates. For type 1 diabetes, transgenic lines expressing nitroreductase under the insulin promoter enable inducible, highly specific beta cell destruction upon metronidazole exposure, producing reproducible insulin deficiency and hyperglycemia while allowing real-time visualization of pancreatic islet regeneration. Adult fish on high-fat or high-cholesterol diets develop obesity, dyslipidemia, and atherosclerosis-like vascular lipid accumulation with conserved lipoprotein metabolism and inflammatory pathways. Storage diseases are equally tractable: the zebrafish model of Fabry disease, lacking alpha-galactosidase A activity, revealed an independent mechanism of kidney damage driven by mitochondrial alterations and disturbed glycolysis and galactose metabolism, beyond the canonical lysosomal accumulation of globotriaosylceramide.

Immunology and cardiology round out the model’s portfolio with distinctive technical advantages. During the first week of life, zebrafish larvae possess only a functional innate immune system, with adaptive immunity developing weeks later—a temporal separation that permits selective investigation of neutrophil and macrophage responses without adaptive interference. Transgenic reporter lines such as Tg(mpx:GFP) for neutrophils and Tg(mpeg1:mCherry) for macrophages enable direct visualization of leukocyte migration and host–pathogen interactions in living organisms. Infection of larvae with Mycobacterium marinum, closely related to Mycobacterium tuberculosis, recapitulates the hallmark organized granulomas of human tuberculosis and has enabled identification of virulence factors, host defense mechanisms, and high-throughput screening for novel antitubercular drugs, while reporter lines tracking autophagy marker LC3 recruitment to bacterial vacuoles illuminate cell-autonomous immunity against Staphylococcus aureus and Salmonella Typhimurium. In cardiology, homologs of key cardiac ion channels including hERG make zebrafish respond to QT-prolonging drugs comparably to humans: a landmark study identified 22 of 23 clinically relevant proarrhythmic compounds as positive in the assay, a drug-sensitized screen uncovered 15 genes affecting cardiac repolarization including GINS3, and screening of 3,000 compounds in a doxorubicin-induced cardiomyopathy model yielded the cardioprotective molecules visnagin and diphenylurea, subsequently validated in mice. Adult zebrafish uniquely regenerate cardiac muscle after injury through cardiomyocyte dedifferentiation and proliferation—a capacity absent in mammals—making the fish an unmatched system for heart regeneration research.

The recommendations arrive against a sobering backdrop of preclinical failure. The overall preclinical-to-market attrition rate exceeds 92 percent, a figure unchanged for three decades. Mouse models produce positive preclinical results in 90 to 95 percent of studies, yet fewer than 8 to 10 percent translate to approved drugs, falling to 3.5 percent in oncology—a gap attributed less to mouse biology than to study design, publication bias, sex bias, lack of genetic diversity, and failure to reproduce the full complexity of human immunology and metabolism. Notably, zebrafish under 120 hours post-fertilization, which do not swim or feed independently, are considered New Alternative Methodologies under EU Directive 2010/63, and the FDA has developed a draft on NAM use in preclinical research paving the way for zebrafish in these studies. The Society frames the fish as the most productive early-stage preclinical pipeline: an intermediate platform positioned between simple in vitro systems and resource-intensive mammalian studies, used to prioritize compounds, identify early toxicity signals, and refine hypotheses before mammalian validation. Implementation, the authors stress, requires question-driven design, standardized protocols with defined developmental stages, exposure windows, and controls, robust biologically relevant endpoints, and predefined criteria for progression to mammalian models. With zebrafish now the second most frequently used animal model in EU research after mice, the Society calls on research institutions, pharmaceutical companies, and regulatory agencies to systematically incorporate these embryo and larval assays into efficacy and safety evaluation, grant applications, and research standards—an integration the authors argue will yield more humane, efficient, and innovative science, ultimately benefiting medical progress and public health.

Subject of Research: Use of the zebrafish (Danio rerio) model in biomedical research and its recommendations for replacing mammalian models

Article Title: Recommendations of the Polish Zebrafish Society on the use of the zebrafish (Danio rerio) model in biomedical research

Article References: Podlasz, P., Migocka-Patrzałek, M., Prajsnar, T. K., Sarosiak, A., & Tylzanowski, P. (2026). Recommendations of the Polish Zebrafish Society on the use of the zebrafish (Danio rerio) model in biomedical research. Acta Biochimica Polonica, 73, Article 16545. https://doi.org/10.3389/abp.2026.16545

Image Credits: AI Generated

DOI: 10.3389/abp.2026.16545

Keywords: zebrafish, Danio rerio, 3Rs principles, preclinical research, drug discovery, toxicology, oncology, xenograft, cardiotoxicity, epilepsy, diabetes, immunology

PFAS are a large family of synthetic chemicals used for decades in products ranging from nonstick cookware and water-repellent fabrics to food packaging and firefighting foams. Their strong carbon-fluorine bonds make them extremely resistant to degradation, earning them the nickname “forever chemicals.” They are now detected in water supplies, soil, wildlife, and human blood worldwide, and epidemiological studies have associated PFAS exposure with elevated cholesterol, liver injury, immune dysfunction, and certain cancers.

To investigate how PFAS might contribute to metabolic liver disease, researchers exposed mice to representative PFAS compounds and tracked changes in liver fat accumulation, metabolic markers, and the composition of the gut microbiome. The animals developed hallmark features of fatty liver disease, including increased hepatic lipid buildup and inflammation-related signaling.

Analysis of the gut microbiome revealed that PFAS exposure substantially altered the community of bacteria residing in the intestines. Certain bacterial groups that are typically associated with healthy metabolic function declined, while other taxa expanded. The researchers found that these microbial shifts correlated with changes in bile acid metabolism, a key pathway through which gut bacteria communicate with the liver and regulate fat processing.

Bile acids are synthesized in the liver from cholesterol and then modified by gut bacteria before being reabsorbed and returned to the liver. This enterohepatic circulation allows gut microbes to influence hepatic lipid metabolism, glucose regulation, and inflammatory signaling. The study found that PFAS exposure disrupted this normal bile acid cycling, altering the balance of bile acid species that reach the liver and thereby contributing to abnormal fat accumulation in hepatic tissue.

When the researchers transferred gut bacteria from PFAS-exposed mice to germ-free mice, the recipients developed liver changes resembling those seen in the exposed animals, providing evidence that the altered microbiome itself can transmit the disease-promoting effects. Conversely, interventions aimed at supporting beneficial gut bacteria partially mitigated the liver abnormalities in PFAS-exposed mice, suggesting that microbial pathways mediate a meaningful portion of the toxicity.

The findings add to growing evidence that the gut-liver axis is a critical mediator of how environmental chemicals affect metabolic health. Previous research has shown that other pollutants, including certain pesticides and plasticizers, can also reshape gut microbial communities in ways that promote metabolic dysfunction. The new work extends this framework to PFAS, one of the most pervasive classes of environmental contaminants.

The researchers caution that mouse studies do not directly establish the same mechanisms in humans, and that human PFAS exposure typically involves complex mixtures of many different compounds at varying doses. Nevertheless, the identification of a microbiome-mediated pathway opens potential avenues for intervention. Strategies such as dietary modifications, probiotics, or targeted microbial therapies might one day help reduce the liver-related health burden of PFAS exposure, particularly in heavily affected communities.

With PFAS contamination now recognized as a global public health challenge, understanding the full range of biological pathways through which these chemicals cause harm is increasingly urgent. This study highlights that the trillions of microbes inhabiting the human gut may be an important and previously underappreciated target of PFAS toxicity, and that protecting microbial health could become part of the broader strategy for mitigating the consequences of environmental chemical exposure.

The disconnect between the two topics is notable: while the PFEx chemistry article deals with designed P(V)-F electrophiles, the PFAS liver study concerns environmental organofluorine persistence. Both hinge on the carbon-fluorine and phosphorus-fluorine bonds, but their fates in biological systems could not be more different. PFEx reagents are engineered to react selectively and then be metabolized or excreted, whereas PFAS compounds owe their environmental longevity to the extraordinary strength of their C-F bonds, which resist enzymatic and chemical degradation. This contrast underscores a broader theme in modern fluorine chemistry: the same bond motif can be either a liability or an asset depending on molecular context, design intent, and the biological environment in which it finds itself.

From a medicinal chemistry standpoint, the latent electrophilicity of P(V)-F functionalities offers a conceptual advantage over classical covalent warheads. Traditional covalent inhibitors, such as acrylamides reacting with cysteine residues, rely on electrophiles that are continuously reactive, raising concerns about off-target modification of unrelated proteins. PFEx chemistry, by contrast, exploits a proximity-driven mechanism in which the P-F bond remains largely inert until brought into close apposition with a nucleophilic residue by specific molecular recognition. This environment-dependent activation mirrors strategies seen in nature, where enzymes position substrates precisely to achieve selectivity that would be impossible with freely diffusing reactive species. The result is a class of chemical tools whose reactivity is gated by binding events rather than by bulk concentration alone.

The genetic code expansion work described in the source is particularly significant for the field of covalent biology. By incorporating phosphoramidofluoridate-containing unnatural amino acids such as PFY and PFK at defined positions within proteins, researchers can in principle direct covalent bond formation to specific interaction interfaces without requiring metal catalysts or external activation. This catalyst-free feature is operationally important for live-cell experiments, where metal catalysts like those used in CuAAC can be cytotoxic or interfere with cellular processes. The ability to perform such modifications both in vitro and in mammalian cells suggests that PFEx-based UAAs could become standard tools for mapping protein-protein interactions, stabilizing transient complexes, or creating covalent analogs of otherwise reversible binding events.

The breadth of nucleophilic residues that PFEx can engage, including lysine, histidine, tyrosine, and cysteine, distinguishes it from SuFEx-based approaches that have historically been more limited in the range of amino acid side chains they can modify stably. Lysine residues are abundant on protein surfaces but often poorly targeted by existing covalent chemistries; histidine and tyrosine are similarly underrepresented in the covalent inhibitor literature. Expanding the residue palette available for site-specific covalent modification opens new possibilities for targeting proteins that lack cysteine or other conventionally druggable nucleophiles near their active sites, potentially broadening the scope of the covalent drug discovery enterprise.

The application of fluorophosphonate-based electrophiles in activity-based protein profiling represents a complementary strategy to genetic code expansion. Rather than installing reactive handles at predetermined sites, ABPP uses broad-spectrum probes to survey entire proteomes for enzymes whose active sites are catalytically competent to activate the P-F bond. This approach has been particularly productive for serine hydrolases, a large enzyme family implicated in lipid metabolism, inflammation, and neurodegeneration. By combining ABPP with quantitative mass spectrometry, researchers can identify which members of this family are active in specific cell types or disease states, providing functional information that transcriptomics alone cannot supply. The mechanistic overlap between fluorophosphonate reactivity and PFEx chemistry suggests that insights gained from decades of ABPP probe design could inform the next generation of PFEx-based chemical biology tools.

Looking forward, several challenges remain before PFEx chemistry reaches routine adoption. The hydrolytic stability of P(V)-F bonds under ambient conditions is a strength for storage and handling but raises questions about long-term fate in biological systems and the environment. Understanding how phosphoramidofluoridate linkages are processed by cellular machinery, whether they are recognized by phosphatases or other hydrolases, and whether their breakdown products are benign will be essential for translational applications. Additionally, comparative studies systematically evaluating PFEx against SuFEx and other covalent chemistries in terms of proteome-wide selectivity, immunogenicity, and pharmacokinetic behavior are still limited. As the field matures, such head-to-head evaluations will be necessary to define the optimal applications for each chemistry and to guide rational probe and therapeutic design.

The convergence of PFEx chemistry with genetic code expansion, activity-based profiling, and proximity-induced target binding reflects a broader trend in chemical biology toward precision covalent interventions. Rather than relying on stochastic encounters between reactive groups and protein surfaces, the field is increasingly designing systems in which covalent bond formation is contingent on specific molecular recognition events. This paradigm, sometimes described as proximity-induced covalent inhibition, has already yielded clinical successes with targeted covalent inhibitors and is likely to benefit from the unique reactivity profile that P(V)-F electrophiles provide. As synthetic methods for preparing diverse PFEx-enabled building blocks improve and as our understanding of their biological behavior deepens, these tools are positioned to contribute meaningfully to both fundamental discovery and therapeutic development.

Subject of Research: Health

Article Title: Phosphorus fluoride exchange (PFEx): a new frontier in bioconjugation, enzyme inhibition, proximity-induced target-binding and fluorescence probes

Article References: Gupta, V., Roy, N., Newaskar, V., & Guchhait, S. K. (2026). Phosphorus fluoride exchange (PFEx): a new frontier in bioconjugation, enzyme inhibition, proximity-induced target-binding and fluorescence probes. Frontiers in Chemical Biology, 5, Article 1879339. https://doi.org/10.3389/fchbi.2026.1879339

Image Credits: AI Generated

DOI: 10.3389/fchbi.2026.1879339

Keywords: PFAS, fatty liver disease, gut microbiome, liver disease, environmental health, toxicology, Phosphorus, fluoride, exchange, PFEx, frontier, bioconjugation

What sets this study apart from much of the existing toxicology literature is the model system. Scientists have long suspected a link between so-called endocrine-disrupting chemicals and breast cancer risk, but most of that evidence has come from animal models or from flat layers of laboratory-grown cells that fail to capture the architecture and behavior of genuine human tissue. The breast is an unusual organ in this respect. Unlike most structures in the body, it undergoes major developmental remodeling long after birth, most dramatically during puberty and pregnancy. Charlotte Kuperwasser, the study’s senior author and a professor of developmental, molecular, and chemical biology at Tufts University School of Medicine, emphasized that this extended developmental window is precisely what makes the breast potentially vulnerable. Breast tissue cells, she noted, may be highly sensitive to environmental cues such as chemical exposure during these critical periods of mammary gland development.

To approximate that complexity in the laboratory, the team turned to three-dimensional models known as organoids, grown from breast tissue donated by 13 healthy young women. Organoids are miniature, self-organizing tissue cultures that contain multiple cell types found in the native organ. In this case, the breast organoids reproduced key aspects of how human breast tissue actually develops, branching and maturing in a way that standard two-dimensional cell cultures simply cannot. This meant the researchers could watch, in real time and at molecular resolution, what happens when developing human breast tissue encounters chemicals at concentrations people actually experience.

Over roughly three weeks of development, the organoids were exposed to a panel of individual chemicals and chemical mixtures. The selection was deliberately broad, encompassing endocrine-disrupting chemicals that interfere with hormones, compounds that affect cellular metabolism, and agents known or suspected to cause cancer. After exposure, the researchers analyzed molecular changes across the tissue, including shifts in gene activity and alterations in DNA modifications—epigenetic marks that regulate which genes are switched on or off without changing the underlying genetic sequence. The results showed that different chemicals affected tissue development in different ways, but the most consequential finding involved three structurally related compounds: bisphenol A (BPA), bisphenol S (BPS), and bisphenol F (BPF).

BPA is the notorious veteran of this family, widely known as a component of certain plastics and food-can linings. BPS and BPF are the chemical cousins that industry increasingly adopted as BPA came under regulatory and consumer scrutiny. Individually, at the doses tested, each of the three bisphenols produced relatively few changes in the developing organoids. The surprise came when the researchers combined them. Applied together at very low concentrations—levels comparable to those actually detected in human blood and urine—the bisphenol mixture disrupted normal breast development in organoids derived from most of the donors. This convergence matters because real-world human exposure rarely involves a single compound in isolation. Kuperwasser explained that the team intentionally used concentrations relevant to real-world exposure rather than the very high doses sometimes deployed in toxicology studies, and tested mixtures precisely because people are typically exposed to multiple chemicals simultaneously.

The next step pushed the findings into territory with direct clinical resonance. The researchers compared the molecular signature induced by the bisphenol mixture with molecular data from human breast cancers. The exposure-associated pattern aligned most strongly with data from patients diagnosed with invasive lobular carcinoma, a subtype of breast cancer with a distinctive character. Lobular carcinomas arise in the lobules of the breast and often grow in diffuse patterns that do not form a detectable lump, making them notoriously difficult to catch with standard mammography. It is important to stress what this comparison does and does not demonstrate. It does not establish that bisphenols cause lobular cancer, nor does it explain the mechanism by which the observed molecular changes might contribute to disease. What it shows is a suggestive overlap: tissue reprogrammed by low-dose chemical mixtures in the laboratory bears epigenetic resemblance to a cancer subtype that is hard to detect and understudied.

The conceptual leap the authors propose is a rethinking of how environmental exposures fit into cancer risk. Historically, Kuperwasser observed, cancer risk has been framed largely in terms of inherited mutations, lifestyle factors, and exposures that directly damage DNA, such as radiation or tobacco carcinogens. These findings raise another possibility: environmental exposures may subtly alter how normal tissues develop, leaving behind molecular changes that do not cause cancer on their own but may render the tissue more permissive to malignant transformation many years later. In this framing, the relevant harm is not genotoxic damage but a kind of developmental detour—epigenetic rewiring that persists quietly in otherwise healthy tissue and lowers the barriers that a future initiating event would need to overcome.

That persistence points toward a practical application. If the molecular alterations induced by chemical exposure survive in human tissues over time, they could function as a biological record of past exposure—a scar written in epigenetic marks. Kuperwasser suggested that if such markers are validated in people, they could potentially help identify individuals at higher risk of breast cancer and inform earlier or more targeted screening strategies. For a disease in which early detection dramatically improves outcomes, and in which risk assessment currently relies heavily on family history and genetic variants that explain only a fraction of cases, a biomarker reflecting cumulative environmental exposure would fill a genuine gap in preventive medicine.

Substantial caveats remain, and the researchers are explicit about them. The organoids came from 13 donors, a sample size that cannot capture the full genetic and developmental diversity of the population, and the study involved a limited panel of chemicals and mixtures. The field will need larger and more diverse cohorts of tissue donors, a wider range of chemical exposures, and longitudinal studies to determine how broadly the findings apply and whether the molecular changes observed in organoids correlate with actual breast disease in people. Validation in human populations is the essential next step before any clinical translation. Still, the study establishes a methodological foundation: a human-relevant, three-dimensional system in which the long-suspected effects of everyday chemical mixtures on breast development can finally be observed and quantified.

The research was led by co-first authors Meadow Parrish and Meloryn Seraj, both PhD students in genetics, molecular, and cellular biology at Tufts Graduate School of Biomedical Sciences, and was supported by the Find The Cause Breast Cancer Foundation. The authors declare no competing interests. If the results hold up under further scrutiny, they could change how scientists and public health authorities think about cancer prevention—shifting attention from purely genetic and lifestyle determinants toward the cumulative, low-dose chemical environment that surrounds human development from puberty onward. For now, the study stands as a technical achievement with an urgent message: the chemistry of everyday life may be writing itself into the biology of human tissue, and for the first time, researchers have a tool capable of reading it.

Subject of Research: How endocrine-disrupting chemical mixtures alter normal human breast tissue development and may shape breast cancer risk.

Article Title: Study finds common chemicals may alter normal breast development

Article References: Study finds common chemicals may alter normal breast development. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: bisphenols, BPA, endocrine-disrupting chemicals, breast cancer, organoids, epigenetics, mammary gland development, invasive lobular carcinoma, chemical mixtures, Tufts University, PNAS, toxicology

The review, led by researchers who have spent years working with pregnant baboons, surveys the milestones of prenatal brain maturation in nonhuman primates and catalogs how environmental insults—air pollution, ionizing radiation, toxic metals, pesticides, viral and bacterial infections, excess heat, and drugs of abuse—can derail them. The stakes are considerable. The fetal brain undergoes its most dramatic expansion during gestation, laying down the cortical layers, cerebellar circuits, and vascular networks that will support cognition and behavior for a lifetime. Disruptions during this window can produce long-term cognitive, emotional, and behavioral deficits, and identifying the moments of greatest sensitivity is central to prevention.

What makes the baboon so valuable is a matter of timing and anatomy. Rodents are altricial animals: their brains at birth correspond roughly to a human fetus in the third trimester, so many developmental processes that occur before birth in people happen after birth in mice and rats. In baboons and humans, by contrast, key steps of cerebellar development unfold during gestation itself. The external granule cell layer of the cerebellum, a proliferative zone that produces the granule neurons governing motor control and motor learning, can be tracked in fetal baboon tissue using molecular markers such as Pax6, which labels progenitor cells; Ki67, which marks dividing cells; and Tag1, which flags neurons that have begun to differentiate. Quantifying these cell populations offers a direct readout of whether an environmental insult has disturbed cerebellar development—a process that in rodents would be largely postnatal and therefore harder to align with human pregnancy.

The parallels extend across the entire brain. Baboons share roughly 92 percent of their genomic sequence with humans, and like us they possess a gyrencephalic cortex, folded into gyri and sulci rather than smooth. Imaging studies show that baboon brain volume and cortical surface area are highly heritable, that the corpus callosum follows a developmental trajectory closely mirroring the human one, and that grey-to-white matter ratios, myelination, and cortical laminar development share strong temporal and structural similarities with our own species. Even the cerebellum’s molecular layer thickens in late gestation and early infancy in both baboons and humans, reflecting comparable maturation of Purkinje cells.

The vascular system tells a similar story. By gestational day 120, corresponding to the end of the human second trimester, the four major cerebral arteries—anterior, middle, posterior, and basilar—are already distinguishable in the baboon fetus. By day 165, the third-trimester equivalent, fetal cerebral arteries can constrict in response to elevated intraluminal pressure, demonstrating myogenic tone, and they respond robustly to depolarizing stimuli such as potassium chloride, showing that smooth muscle contractility is being established in utero. The neurovascular unit—neurons, astrocytes, and endothelial cells—is remarkably conserved across primates, and primate brains arrive at birth with more advanced vascular networks than rodents, supporting the prolonged cortical development, including postnatal neurogenesis and gyrification, that characterizes our species.

Against this backdrop, the review assembles the evidence on environmental threats. Heavy metals cross the placental barrier with ease: arsenic is associated with miscarriage, stillbirth, and intrauterine growth restriction through oxidative stress and endocrine disruption; cadmium with preterm birth and small-for-gestational-age infants, possibly by interfering with placental nutrient transport; lead with low birth weight and impaired neurodevelopment; and methylmercury, accumulated from contaminated seafood, with lasting cognitive and motor deficits. Notably, a study of pregnant baboons measured forty elements across maternal and fetal blood, hair, nails, placenta, amniotic fluid, and fetal tissues, and found that element concentrations closely mirrored those of late-stage human pregnancies—reinforcing the baboon’s value for studying both normal maternal-fetal physiology and toxicology.

Physical and biological insults leave their own signatures. Excessive doses of ionizing radiation, above 0.1 gray, can cause miscarriage, growth restriction, malformations, and reduced cognitive function, with sensitivity depending on gestational stage; baboon studies have identified biomarkers such as aspartate aminotransferase, LDH, Flt3-ligand, and the neutrophil-to-lymphocyte ratio that distinguish total-body from partial-body irradiation and could guide treatment after accidental exposure. Maternal hyperthermia in pregnant baboons—body temperature of 41 to 42 degrees Celsius without fever—produced fetal blood pressure drops, elevated heart rate, severe acidosis, hypoxia, and hypercapnia, and doubled uterine contractility, raising the risk of preterm birth. Viral infections tell perhaps the starkest story: in baboons, herpesvirus papio 2 and cytomegalovirus cause placentitis with seroprevalence reaching 95 percent, and perinatal Zika virus infection produces significant fetal cerebral cortical injury that can end in fetal death.

Alcohol receives particularly detailed attention, and the baboon data are sobering. Three episodes of maternal alcohol exposure during the second-trimester equivalent, producing maternal blood alcohol levels around 80 milligrams per deciliter—the legal driving limit in most of the United States—caused fetal growth restriction, with amniotic fluid levels reaching 63 milligrams per deciliter, near the threshold of noticeable behavioral impairment in humans. Near term, exposed offspring showed reduced abdominal and head circumferences. A single binge episode, modeled with a gastro-nasal catheter delivering 3 grams of ethanol per kilogram to approximate a blood alcohol concentration of 0.2 percent—the equivalent of six to eight drinks in two hours—increased placental permeability and fetal brain perfusion, paradoxically making the fetal brain more vulnerable to toxic insult. Moderate doses during the second trimester dilated the middle cerebral artery, an effect reversed by blocking cannabinoid CB1 and CB2 receptors, and proteomic profiling revealed lasting alterations in mitochondrial and cytoskeletal proteins of cerebral arteries exposed earlier in gestation.

Cannabinoids and tobacco complete the picture. Roughly 5 percent of pregnant women self-medicate with marijuana, and chronic prenatal THC exposure in rhesus macaques altered fetal brain growth on MRI, with cerebrospinal fluid microRNAs pointing to disrupted axonal guidance and netrin signaling. Quantitative PCR in fetal baboon cerebellum confirms that both cannabinoid receptor genes, Cnr1 and Cnr2, are expressed at gestational day 120, the end of the second-trimester equivalent—meaning the fetal endocannabinoid system, which regulates synaptogenesis and circuit maturation, is present and potentially disruptable exactly when THC arrives. Epigenetic changes after prenatal cannabinoid exposure may even persist across generations, and are linked to psychiatric conditions including autism spectrum disorder, ADHD, and schizophrenia. Perinatal exposure to environmental tobacco smoke in rhesus monkeys selectively upregulated nicotinic acetylcholine receptors in the brainstem and cortex, a hallmark of nicotine neuroteratogenesis, while prenatal alcohol exposure in macaques and vervet monkeys reduced hippocampal and cortical neuron numbers and disrupted miRNA regulation of genes critical for synaptic development, including a previously unknown link to the EFNB1 gene.

The authors acknowledge that nonhuman primate research carries significant ethical and logistical burdens—long lifespans, complex care, strict welfare requirements—but they argue the translational payoff justifies the investment. Rodent preclinical results frequently fail in human clinical trials, a gap that may stem from precisely the developmental and vascular differences the baboon model is positioned to resolve. Computational models already predict that primates, including humans, are more sensitive to ethanol’s inhibition of neocortical neuronal proliferation than rodents, with significant neuronal deficits at blood alcohol concentrations equivalent to a single standard drink within an hour. As cannabis legalization reshapes perceptions of safety, as air pollution and heat extremes intensify, and as viral threats continue to emerge, the baboon offers a rare window into the mechanisms by which the prenatal environment writes itself into the developing brain—and a foundation for the prevention and treatment strategies that neurodevelopmental medicine urgently needs.

Subject of Research: Prenatal environmental exposures and fetal brain development studied with baboon and other nonhuman primate models

Article Title: Prenatal environmental exposures and brain development: studies with baboons and other nonhuman primates

Article References: Iskusnykh, I. Y., Thapa, S., Chizhikov, V. V., & Bukiya, A. N. (2025). Prenatal environmental exposures and brain development: studies with baboons and other nonhuman primates. Advances in Drug and Alcohol Research, 5, Article 14858. https://doi.org/10.3389/adar.2025.14858

Image Credits: AI Generated

DOI: 10.3389/adar.2025.14858

Keywords: neuroscience, developmental biology, toxicology, baboon model, fetal brain, prenatal exposure, FASD, cannabinoids, Prenatal, environmental, exposures, brain

The mechanics behind the Article in Press model reveal how deeply digital infrastructure has reshaped the economics and tempo of scholarly publishing. In the traditional print-era workflow, a paper accepted by a journal would wait in a queue for an issue to be assembled, typeset, printed, and distributed, a process that could consume several months. The early-access approach decouples acceptance from publication. The accepted, peer-reviewed manuscript is posted as submitted or lightly processed, clearly labelled online to show that it is not the final Version of Record. Because the DOI is assigned at this stage, citations accumulate from the moment the paper becomes visible, and the citation record carries forward seamlessly: when the final Version of Record is published, it replaces the Article in Press under the same DOI, so no reference ever breaks.

That permanence of the identifier is more than a technical convenience. It solves a problem that plagued early experiments with online-first publishing in the late 1990s and 2000s, when preliminary web versions sometimes carried different identifiers or no identifiers at all, fragmenting the citation trail. Under the current model, the DOI acts as a stable thread running through every stage of a paper’s life. A researcher who cites the Article in Press version today is citing the same object that will exist as the Version of Record tomorrow. This continuity matters for meta-analyses, systematic reviews, and clinical guidelines, all of which depend on citation records that remain coherent over decades.

The system is not without caveats, and the journals that use it are explicit about them. An Article in Press may be subject to further editing, because errors affecting the content can be discovered during the final production process. Errors in the early-access version are corrected during the author proofing stages of production, and those corrections are reflected in the final Version of Record. In practice, this means the version a reader encounters online immediately after acceptance is a snapshot of the peer-reviewed manuscript, not a polished, typeset artifact. Figures may be reformatted, references may be rechecked, and copyediting may adjust phrasing. The scientific substance has passed peer review, but the presentation is still in transit.

For readers, the labelling is the critical safeguard. Every Article in Press is clearly marked online to indicate that it is not the final Version of Record, and all legal disclaimers relating to the journal apply to it. This transparency matters most in fast-moving or high-stakes fields. In pharmacology and toxicology, where a single paper on a drug’s toxicity profile can be picked up by clinicians, journalists, and regulators within hours of appearing online, the distinction between a peer-reviewed but not-yet-final manuscript and a fully published Version of Record is a meaningful one. The labelling system exists precisely so that downstream users can weigh the evidence appropriately, understanding that the peer-review filter has already been applied even though production remains incomplete.

The open-access dimension adds another layer of significance. Fully open-access journals provide this early-access service on every accepted manuscript, meaning that no accepted paper waits behind a production queue before becoming publicly visible. This has a democratizing effect on the speed of science. A researcher in a low-resource setting, a clinician in a community hospital, or a journalist covering a public health story can all access the accepted findings at the same moment as researchers at elite institutions. The traditional lag between acceptance and publication, which once created an information asymmetry favoring those with library access to the fastest journals, is effectively eliminated at the moment of acceptance.

Behind the scenes, the workflow that makes this possible involves a coordinated sequence of editorial and production steps. Once peer review concludes and the editors issue a formal acceptance, the manuscript enters the production pipeline. The Article in Press version is generated from the accepted files, assigned its DOI, and posted to the journal’s online platform. Author proofing then begins, in which the authors review the typeset version and flag errors. Corrections discovered at this stage are folded into the Version of Record. The process acknowledges a simple truth about scholarly publishing: even after peer review, the transformation of a manuscript into a finished published article involves human steps that can introduce or reveal errors, and the early-access model builds in a visible, correctable intermediate state rather than pretending the first online appearance is flawless.

For authors, the practical implications are significant. An accepted paper begins accruing citations, visibility, and potential media attention immediately, which can matter for grant applications, tenure timelines, and career progression. But authors also carry a responsibility during the proofing stage, because errors they fail to catch will persist into the Version of Record. Journals that use the Article in Press model typically encourage authors organizing press releases to contact their production editor as early as possible, ensuring that media coverage aligns with the availability and status of the paper. The coordination between publicity and publication status is a small but telling detail: it reflects an awareness that early-access papers enter the public sphere before they are finalized, and that communication about them should reflect that status honestly.

The broader significance of the Article in Press model lies in what it reveals about the changing tempo of science itself. Research in areas such as infectious disease, toxicology, and pharmacology increasingly unfolds on timelines measured in weeks, not years, and the publishing ecosystem has adapted accordingly. The early-access approach preserves the essential checkpoints of peer review and formal publication while removing the artificial delay between them. It treats the DOI as the permanent anchor of a paper’s identity and treats the published record as a sequence of improving versions rather than a single fixed event. For readers, the takeaway is straightforward but important: when you encounter a paper labelled as an Article in Press, you are looking at peer-reviewed science that has been accepted and made permanently citable, but not yet finalized. The findings are real and reviewable, the identifier is stable, and the final version will arrive under the same DOI, correcting any residual errors along the way. In an era when the speed of dissemination shapes the pace of discovery, that combination of immediacy and transparency has quietly become one of the most important infrastructures in scientific communication.

Subject of Research: Early-access publishing of accepted peer-reviewed manuscripts as Articles in Press with permanent DOIs

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Article in Press, peer review, DOI, open access, scholarly publishing, Version of Record, pharmacology, toxicology, scientific communication, early access, citation, BMC